Projects per year
Personal profile
Personal profile
After serving as a Research Assistant in the Department of Statistics and Actuarial Science at the University of Waterloo, Dr. Xu received her academic appointment in 2003 as an Assistant Professor in the Center of American Indian Health Research of the College of Public Health at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. She joined Houston Methodist Research Institute in 2007. Dr. Xu is an Associate Research Professor of Biostatistics in the Center for Outcomes Research and Houston Methodist DeBakey Heart & Vascular Center at Houston Methodist Research Institute.
Research interests
Dr. Xu’s biostatistics work has primarily focused on cardiovascular disease (CVD), diabetes, renal disease, and cancer. She was the biostatistician for the NIH-funded Strong Heart Study, the largest and longest longitudinal study of cardiovascular disease and its risk factors in American Indians.
Dr. Xu’s current biostatistics studies include NIH and DoD-funded studies in brain metastatic tumors and breast cancer.
Education/Academic qualification
Statistics, PhD, University of Waterloo, Canada
Jul 1 1999 → Jun 30 2003
Statistics, MS, York University, Toronto, Canada
Jul 1 1998 → Jun 30 1999
BSc, Sichuan University
Jul 1 1982 → Jun 30 1986
External positions
Assistant Professor of Biostatistics in Medicine, Weill Cornell Medicine
Mar 1 2010 → …
Research Area Keywords
- Outcomes, Quality & Health Care Performance
- Systems Medicine & Bioinformatics
Free-text keywords
- Biostatistics
- Clinical trial data analysis
- Survival data analysis
- Longitudinal data analysis
- Cardiovascular disease
- Diabetes
- Kidney disease
- Nutrition
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
5-Fluorouracil/?Leucovorin (5FU/?LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Abdelrahim, M. (PI), Abanonu, C. (Key Personnel), Esmail, A. (Key Personnel), Guan, J. (Key Personnel), Heyne, K. (Key Personnel), Singh, M. (Key Personnel) & Xu, S. (Key Personnel)
5/8/25 → …
Project: Clinical Trial
-
S100A4 mediated immune suppression in GBM
Yun, K. (PI) & Xu, S. (Key Personnel)
4/1/21 → 1/31/26
Project: Federal Funding Agencies
-
Real-world experience with Tecentriq + Avastin for the treatment of hepatocellular carcinoma (HCC) in the US
Abdelrahim, M. (PI), Connor, A. A. (Key Personnel), Dacha, S. (Key Personnel), Esmail, A. (Key Personnel), Esnaola, N. F. (Key Personnel), Ghobrial, R. M. (Key Personnel), Graviss, E. A. (Key Personnel), Gupta, N. (Key Personnel), Heyne, K. (Key Personnel), Kloc, M. (Key Personnel), Kodali, S. (Key Personnel), Mobley, C. M. (Key Personnel), Moore, L. W. (Key Personnel), Noureddin, M. (Key Personnel), Rizk, E. (Key Personnel), Victor, III, D. W. (Key Personnel) & Xu, S. (Key Personnel)
Project: Clinical Trial
-
Nanotechnology-based targeting of breast cancer liver metastases
Godin, B. (PI), Chen, S.-H. (Key Personnel), Niravath, P. A. (Key Personnel), Rosato, R. R. (Key Personnel) & Xu, S. (Key Personnel)
3/1/21 → 2/28/25
Project: Federal Funding Agencies
-
Therapeutic Potential of Flavopiridol in the Suppression of Lung Fibrosis Via CDK9 Inhibition: American Journal of Respiratory and Critical Care Medicine
Xu, J., Chang, W.-H., Chaudhary, S., Chang, S.-Y., Hsu, S.-W., Liu, G.-Y., Haudenschild, D. & Chen, C.-H., 2025, In: American journal of respiratory and critical care medicine. 211, Abstracts, p. A4698-A4698Research output: Contribution to journal › Article › peer-review
-
Association of chronic kidney disease with postoperative outcomes: a national surgical quality improvement program (NSQIP) multi-specialty surgical cohort analysis
Riveros, C., Ranganathan, S., Shah, Y. B., Huang, E., Xu, J., Hsu, E., Geng, M., Hu, S., Melchiode, Z., Miles, B. J., Esnaola, N., Klaassen, Z., Jerath, A., Wallis, C. J. D. & Satkunasivam, R., Sep 13 2024, In: BMC Nephrology. 25, 1, p. 305 305.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience
Ranganathan, S., Riveros, C., Xu, S., Hu, S., Geng, M., Huang, E., Melchiode, Z., Zhang, J., Efstathiou, E., Chan, K. S., Wallis, C. J. D., Sonpavde, G. & Satkunasivam, R., Sep 1 2024, In: Urologic Oncology: Seminars and Original Investigations. 42, 9, p. 291.e13-291.e25Research output: Contribution to journal › Article › peer-review
-
Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation
Riveros, C., Ranganathan, S., Haque, W., Huang, E., Xu, J., Kulkarni, G. S., Geng, M., Anis, M., Muhammad, T., Chan, K. S., Farach, A., Teh, B. S., Miles, B. J., Klaassen, Z., Sonpavde, G. P., Wallis, C. J. D. & Satkunasivam, R., Feb 2024, In: Journal of the Canadian Urological Association. 18, 2, p. 17-24 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy database
Melchiode, Z., Hu, S., Xu, J., Riveros, C., Farooq, S., Ranganathan, S., Huang, E., Miles, B. J., Kaushik, D., Wallis, C. J. D. & Satkunasivam, R., Oct 1 2024, In: Urologic Oncology: Seminars and Original Investigations. 42, 10, p. 332.e11-332.e19Research output: Contribution to journal › Article › peer-review